Clinical Features and Response to Systemic Therapy in a Historical Cohort of Advanced or Unresectable Mucosal Melanoma

Melanoma Research - United States
doi 10.1097/cmr.0000000000000306
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Encorafenib/Binimetinib for the Treatment of BRAF-mutant Advanced, Unresectable, or Metastatic Melanoma: Design, Development, and Potential Place in Therapy

OncoTargets and Therapy
OncologyPharmacology
2018English

Renal Pathology and Clinical Associations in Systemic Sclerosis: A Historical Cohort Study

International Journal of General Medicine
Medicine
2019English

Systemic Therapies for Unresectable Locoregional Melanoma: A Significant Area of Need

Melanoma Management
DermatologyOncology
2019English

Systemic Therapy for Previously Untreated Advanced BRAF-mutated Melanoma: Navigating a Shifting Landscape

Immunotherapy
OncologyAllergyImmunology
2017English

Mucosal Tolerance to E-Selectin and Response to Systemic Inflammation

Journal of Cerebral Blood Flow and Metabolism
NeurologyCardiovascular MedicineCardiology
2006English

Systemic Therapy in the Management of Metastatic or Advanced Salivary Gland Cancers

Head & Neck Oncology
2012English

"Clinical-Ct Mismatch" and the Response to Systemic Thrombolytic Therapy in Acute Ischemic Stroke

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2005English

Cessation of Targeted Therapy After a Complete Response in BRAF-mutant Advanced Melanoma: A Case Series

British Journal of Cancer
Cancer ResearchOncology
2016English

Mucosal Melanoma — Clinical Presentation and Treatment Based on a Case Series

Oncology in Clinical Practice
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy